Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...

The US Food and Drug Administration (FDA) has approved a drug for schizophrenia that is exciting the field with an entirely ...

Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...

A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol-Myers Squibb Co., agreeing with counsel for the ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...

One of the first no-brainer dividend stocks to buy with $100 right now is AT&T. At recent prices, America's second-largest telecommunications business by revenue offers a juicy 5.1% dividend yield.

Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...

On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

The FDA approved a new drug for schizophrenia. Discrimination is stressing Chinese Americans and damaging their mental health.

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...